Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2018
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, et al.The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.Cancer Treatment Reviews|August 11, 2025
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancersSilvia Stacchiotti, Pan Pantziarka, Hugh Leonard, et al.Cancer Discovery|June 29, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening InitiativePhilippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.Pageof 7